Catalent Creates New Development & Clinical Segment, Appoints New Leader
August 25, 2009
Catalent Pharma Solutions announces the creation of a new business unit dedicated to helping customers bring new pharmaceutical and biologic products to market. The Development and Clinical Services segment brings together Catalent's analytical and science services and regulatory consulting services, formerly in its Sterile Technologies segment, with its clinical supply services business, formerly included in the Packaging Services segment. Catalent also announces the appointment of Scott Houlton as Group President for the new segment, effective August 31st.
The new segment will build upon Catalent's substantial expertise and proven experience in supporting the development and testing of drugs and biologics through scientific, regulatory and clinical trial supply chain services. For drugs, Catalent provides an unmatched breadth of services, extending from the first steps characterizing a drug molecule to delivery of drugs to the investigator site through the final submission of regulatory filings. For biologics, Catalent's offerings include advanced bioanalytical services, the advanced GPEx® technology and cell-line development services, biomanufacturing, and specialized cold chain distribution for clinical trial materials. For both drugs and biologics, the new segment provides global regulatory consulting and support; respiratory delivery formulation, development and manufacture; early phase injectables manufacture.
Mr. Houlton, 42, most recently served as the Chief Operating Officer of Aptuit, Inc., a global provider of development services, and before that as President of Aptuit's clinical packaging business. Prior to Aptuit, Mr. Houlton held several leadership roles in the development service business of Quintiles Transnational, with prior experience at Cardinal Health and General Electric. Mr. Houlton received a bachelor's degree from Ohio State University, and is a graduate of General Electric's Financial Management training program.
John Chiminski, President and CEO of Catalent, said, "I expect the Development and Clinical Services segment to bring even more value to our customers through a sharpened focus and an integrated approach to solving the challenges our R&D customers face, and believe that this will result in significant new growth for the segment. As we have been involved in more than a third of NDAs and BLAs approved by the FDA in the last seven years, we know what it takes to bring a customer's drug or biologic to market - each step of the way." Mr. Chiminski continued, "I am also very pleased to welcome Scott to Catalent to lead this segment. He is experienced at driving growth, passionate about serving customers, and committed to operational excellence. I expect great things from Scott and the nearly 900 employees of this new segment."
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,500 at 30 facilities worldwide and in fiscal 2008 generated more than $1.8B of annual revenue.
SOURCE: Catalent Pharma Solutions